<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02936206</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 16-1470</org_study_id>
    <nct_id>NCT02936206</nct_id>
  </id_info>
  <brief_title>Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.</brief_title>
  <official_title>Comparison in the Change of Proliferation Index Between Fulvestrant and Tamoxifen in Cyclin D1 +, Estrogen Receptor + Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to microscopically examine breast cancer cells of pre-menopausal&#xD;
      and post-menopausal women before and after exposure to one of the two commonly used breast&#xD;
      cancer drugs, tamoxifen or fulvestrant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The researchers hypothesize that the cyclinD1-interactome can be used to orient the use of&#xD;
      fulvestrant in premenopausal and postmenopausal women. To test this hypothesis, the&#xD;
      researchers propose a pre-surgical randomized clinical trial of tamoxifen vs fulvestrant in&#xD;
      the window between breast cancer diagnosis on core biopsy and definitive surgery. Women with&#xD;
      ER/cyclinD1 positive tumors will be eligible. Response to tamoxifen or fulvestrant will be&#xD;
      evaluated using standard proliferation index as well as gene expression signatures obtained&#xD;
      in pre-clinical models of tamoxifen resistance and sensitivity to fulvestrant. In addition,&#xD;
      the researchers propose to use cutting edge new technology allowing ex-vivo expansion of&#xD;
      primary culture from only a few cancer cells obtained by fine needle biopsy. The researchers&#xD;
      propose to compare the response of these primary cells to patient response. If successful,&#xD;
      the impact of this work can support the expansion of use of fulvestrant to not only&#xD;
      postmenopausal women but premenopausal women as well. In addition, it may serve as a proof of&#xD;
      principle to maximize the use of biopsy material to predict treatment response&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual rate&#xD;
  </why_stopped>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Ki67 Cell Percentage</measure>
    <time_frame>baseline and 2 weeks</time_frame>
    <description>The change in proliferation index as measured by the percentage of cells staining for Ki67 at 2 weeks as compared on baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Estrogen Receptor Level</measure>
    <time_frame>baseline and 2 weeks</time_frame>
    <description>The change in estrogen receptor level at 2 weeks as compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Progesterone Receptor Level</measure>
    <time_frame>baseline and 2 weeks</time_frame>
    <description>The change in progesterone receptor level at 2 weeks as compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Tamoxifen-resistance Gene Expression</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of tamoxifen-resistance gene expression signature observed in patients with cyclinD1 overexpressing breast cancers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Fulvestrant-sensitivity Gene Expression</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of fulvestrant-sensitivity gene expression signature observed in patients with cyclinD1 overexpressing breast cancers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Dose Level</measure>
    <time_frame>2 weeks</time_frame>
    <description>For samples that are available for culture in vivo, proliferation assay to test whether the cells derived from individual patients respond the same as the tumor in vivo in the same patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Cells Staining Positive Within the Breast Tumor</measure>
    <time_frame>2 weeks</time_frame>
    <description>Differential treatment effect for pre and post menopausal subjects assessed by the mean change in levels (expressed as a percentage of cells staining positive within the breast tumor) of ER (and PR) between pre-treatment and post-treatment stratified by menopausal status.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>750 mg injection in 3 divided doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamoxifen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20mg orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only</description>
    <arm_group_label>Fulvestrant</arm_group_label>
    <other_name>Faslodex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>14 days of treatment with tamoxifen 20mg orally each day</description>
    <arm_group_label>Tamoxifen</arm_group_label>
    <other_name>Nolvadex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent prior to beginning specific protocol procedures, including&#xD;
             expected cooperation of the patients for the study treatment regimen and follow-up,&#xD;
             must be obtained and documented according to the local regulatory requirements&#xD;
&#xD;
          -  Adult women greater than 18 years old&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2&#xD;
&#xD;
          -  New diagnosis of invasive cyclin D1 +, ER+, PR +/-, Her2- breast cancer&#xD;
&#xD;
               -  Cyclin D1 positive as defined as a total immunohistochemical score of 5 or&#xD;
                  greater&#xD;
&#xD;
               -  Hormone receptor positive as defined as â‰¥ 10% positive stained cells&#xD;
&#xD;
               -  HER2-normal (IHC score 0-1 or FISH negative [in-situ hybridization (ISH) ratio &lt;=&#xD;
                  2.0 status])&#xD;
&#xD;
          -  Tumor size at least 5 mm with planned primary surgery at Mount Sinai&#xD;
&#xD;
          -  A negative urine dipstick pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Estrogen receptor negative invasive breast carcinoma as defined as less than 10%&#xD;
             stained cells&#xD;
&#xD;
          -  Prior antiestrogen therapy&#xD;
&#xD;
          -  Tumor size less than 5 mm&#xD;
&#xD;
          -  Prior diagnosis of thrombosis or known hypercoagulable state&#xD;
&#xD;
          -  Known history of bleeding diathesis&#xD;
&#xD;
          -  Known liver disease&#xD;
&#xD;
          -  Prior treatment with neoadjuvant therapy&#xD;
&#xD;
          -  Inflammatory breast cancer defined as clinically significant erythema of the breast&#xD;
             and/or documented dermal lymphatic invasion (not direct skin invasion by tumor or peau&#xD;
             d'orange without erythema).&#xD;
&#xD;
          -  Current severe or uncontrolled systemic disease&#xD;
&#xD;
          -  Pregnancy or lactation period. Patients of childbearing potential must implement&#xD;
             adequate non-hormonal contraceptive measures (barrier methods, intrauterine&#xD;
             contraceptive devices) during study treatment.&#xD;
&#xD;
          -  Prior malignancy (including invasive or ductal in-situ breast cancer) within 5 years&#xD;
             prior to randomization, except curatively treated basal cell carcinoma of the skin and&#xD;
             carcinoma in situ of the cervix.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Tiersten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai West</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai St. Luke's</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 14, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <results_first_submitted>April 27, 2021</results_first_submitted>
  <results_first_submitted_qc>April 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2021</results_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Amy Tiersten</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>proliferation Index</keyword>
  <keyword>Tamoxifen</keyword>
  <keyword>Fulvestrant</keyword>
  <keyword>cyclinD1</keyword>
  <keyword>Breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT02936206/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fulvestrant</title>
          <description>750 mg injection in 3 divided doses&#xD;
Fulvestrant: fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only</description>
        </group>
        <group group_id="P2">
          <title>Tamoxifen</title>
          <description>20mg orally&#xD;
Tamoxifen: 14 days of treatment with tamoxifen 20mg orally each day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>There were 2 participants in the study, both randomized to Tamoxifen arm.</population>
      <group_list>
        <group group_id="B1">
          <title>Fulvestrant</title>
          <description>750 mg injection in 3 divided doses&#xD;
Fulvestrant: fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only</description>
        </group>
        <group group_id="B2">
          <title>Tamoxifen</title>
          <description>20mg orally&#xD;
Tamoxifen: 14 days of treatment with tamoxifen 20mg orally each day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Ki67 Cell Percentage</title>
        <description>The change in proliferation index as measured by the percentage of cells staining for Ki67 at 2 weeks as compared on baseline.</description>
        <time_frame>baseline and 2 weeks</time_frame>
        <population>With the 2 patients enrolled on the trial, the data collected was insufficient and not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant</title>
            <description>750 mg injection in 3 divided doses&#xD;
Fulvestrant: fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only</description>
          </group>
          <group group_id="O2">
            <title>Tamoxifen</title>
            <description>20mg orally&#xD;
Tamoxifen: 14 days of treatment with tamoxifen 20mg orally each day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ki67 Cell Percentage</title>
          <description>The change in proliferation index as measured by the percentage of cells staining for Ki67 at 2 weeks as compared on baseline.</description>
          <population>With the 2 patients enrolled on the trial, the data collected was insufficient and not evaluable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Estrogen Receptor Level</title>
        <description>The change in estrogen receptor level at 2 weeks as compared to baseline.</description>
        <time_frame>baseline and 2 weeks</time_frame>
        <population>With the 2 patients enrolled on the trial, the data collected was insufficient and not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant</title>
            <description>750 mg injection in 3 divided doses&#xD;
Fulvestrant: fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only</description>
          </group>
          <group group_id="O2">
            <title>Tamoxifen</title>
            <description>20mg orally&#xD;
Tamoxifen: 14 days of treatment with tamoxifen 20mg orally each day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Estrogen Receptor Level</title>
          <description>The change in estrogen receptor level at 2 weeks as compared to baseline.</description>
          <population>With the 2 patients enrolled on the trial, the data collected was insufficient and not evaluable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Progesterone Receptor Level</title>
        <description>The change in progesterone receptor level at 2 weeks as compared to baseline.</description>
        <time_frame>baseline and 2 weeks</time_frame>
        <population>With the 2 patients enrolled on the trial, the data collected was insufficient and not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant</title>
            <description>750 mg injection in 3 divided doses&#xD;
Fulvestrant: fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only</description>
          </group>
          <group group_id="O2">
            <title>Tamoxifen</title>
            <description>20mg orally&#xD;
Tamoxifen: 14 days of treatment with tamoxifen 20mg orally each day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Progesterone Receptor Level</title>
          <description>The change in progesterone receptor level at 2 weeks as compared to baseline.</description>
          <population>With the 2 patients enrolled on the trial, the data collected was insufficient and not evaluable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Tamoxifen-resistance Gene Expression</title>
        <description>Number of tamoxifen-resistance gene expression signature observed in patients with cyclinD1 overexpressing breast cancers.</description>
        <time_frame>2 weeks</time_frame>
        <population>With the 2 patients enrolled on the trial, the data collected was insufficient and not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant</title>
            <description>750 mg injection in 3 divided doses&#xD;
Fulvestrant: fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only</description>
          </group>
          <group group_id="O2">
            <title>Tamoxifen</title>
            <description>20mg orally&#xD;
Tamoxifen: 14 days of treatment with tamoxifen 20mg orally each day</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Tamoxifen-resistance Gene Expression</title>
          <description>Number of tamoxifen-resistance gene expression signature observed in patients with cyclinD1 overexpressing breast cancers.</description>
          <population>With the 2 patients enrolled on the trial, the data collected was insufficient and not evaluable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Fulvestrant-sensitivity Gene Expression</title>
        <description>Number of fulvestrant-sensitivity gene expression signature observed in patients with cyclinD1 overexpressing breast cancers.</description>
        <time_frame>2 weeks</time_frame>
        <population>With the 2 patients enrolled on the trial, the data collected was insufficient and not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant</title>
            <description>750 mg injection in 3 divided doses&#xD;
Fulvestrant: fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only</description>
          </group>
          <group group_id="O2">
            <title>Tamoxifen</title>
            <description>20mg orally&#xD;
Tamoxifen: 14 days of treatment with tamoxifen 20mg orally each day</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Fulvestrant-sensitivity Gene Expression</title>
          <description>Number of fulvestrant-sensitivity gene expression signature observed in patients with cyclinD1 overexpressing breast cancers.</description>
          <population>With the 2 patients enrolled on the trial, the data collected was insufficient and not evaluable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drug Dose Level</title>
        <description>For samples that are available for culture in vivo, proliferation assay to test whether the cells derived from individual patients respond the same as the tumor in vivo in the same patient.</description>
        <time_frame>2 weeks</time_frame>
        <population>With the 2 patients enrolled on the trial, the data collected was insufficient and not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant</title>
            <description>750 mg injection in 3 divided doses&#xD;
Fulvestrant: fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only</description>
          </group>
          <group group_id="O2">
            <title>Tamoxifen</title>
            <description>20mg orally&#xD;
Tamoxifen: 14 days of treatment with tamoxifen 20mg orally each day</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Dose Level</title>
          <description>For samples that are available for culture in vivo, proliferation assay to test whether the cells derived from individual patients respond the same as the tumor in vivo in the same patient.</description>
          <population>With the 2 patients enrolled on the trial, the data collected was insufficient and not evaluable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Cells Staining Positive Within the Breast Tumor</title>
        <description>Differential treatment effect for pre and post menopausal subjects assessed by the mean change in levels (expressed as a percentage of cells staining positive within the breast tumor) of ER (and PR) between pre-treatment and post-treatment stratified by menopausal status.</description>
        <time_frame>2 weeks</time_frame>
        <population>With the 2 patients enrolled on the trial, the data collected was insufficient and not evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant</title>
            <description>750 mg injection in 3 divided doses&#xD;
Fulvestrant: fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only</description>
          </group>
          <group group_id="O2">
            <title>Tamoxifen</title>
            <description>20mg orally&#xD;
Tamoxifen: 14 days of treatment with tamoxifen 20mg orally each day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Cells Staining Positive Within the Breast Tumor</title>
          <description>Differential treatment effect for pre and post menopausal subjects assessed by the mean change in levels (expressed as a percentage of cells staining positive within the breast tumor) of ER (and PR) between pre-treatment and post-treatment stratified by menopausal status.</description>
          <population>With the 2 patients enrolled on the trial, the data collected was insufficient and not evaluable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>not collected</time_frame>
      <desc>not collected</desc>
      <group_list>
        <group group_id="E1">
          <title>Fulvestrant</title>
          <description>750 mg injection in 3 divided doses&#xD;
Fulvestrant: fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only</description>
        </group>
        <group group_id="E2">
          <title>Tamoxifen</title>
          <description>20mg orally&#xD;
Tamoxifen: 14 days of treatment with tamoxifen 20mg orally each day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Amy Tiersten</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-3300</phone>
      <email>amy.tiersten@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

